Clin2
NCT07550296Possibly a fitRecruiting

Second IV Clot-Dissolving Treatment for Major Stroke

Acute Ischemic Stroke

Part of Brain & nervous system, Heart & circulation clinical trials.

This trial tests giving a second dose of an IV clot-dissolving medicine (prourokinase) to patients who had a stroke from a large clot but didn't improve enough after the first dose. The goal is to see if a second dose within 6 hours of stroke onset can help more patients recover.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 2
Enrollment
122 people
Ages
18 years to 80 years
Study type
Interventional

Who can take part

  • You had a major stroke (large or medium vessel clot) and received IV prourokinase within 4.5 hours of symptom start
  • Your stroke didn't improve much (or got worse) 1 hour after the first treatment, and imaging confirms the clot is still there
  • You have a neurological exam score (NIHSS) of at least 4, and your brain imaging score (ASPECTS) is at least 6
  • You are at least 18 years old and either having your first stroke or a past stroke with no lasting problems
  • You are not scheduled for endovascular thrombectomy (mechanical clot removal) and have no blood clotting disorders

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT07787325Not yet recruiting
Clot-busting drug for stroke within 4.5 hours

This trial tests a clot-busting drug called recombinant human prourokinase for people having an ischemic stroke (a stroke from a blocked blood vessel). The drug is given through an IV within 4.5 hours of symptoms to help restore blood flow and potentially reduce disability.

Hefei, Anhui
NCT07776873Not yet recruiting· Phase 3
Clot-busting drug for stroke blockages up to 24 hours

This trial tests a medicine given through a vein to break up blood clots in medium-sized brain arteries. It may help people who had a stroke between 4.5 and 24 hours ago and cannot have the standard clot-removal procedure.

Hefei, Anhui
NCT07617870Not yet recruiting· Phase 3
Pro-urokinase for Recent Posterior Brain Strokes

This trial tests a clot-dissolving medication (pro-urokinase) for people with recent strokes in the back of the brain. You would be treated 4.5 to 9 hours after symptoms start, which is beyond the typical treatment window, using special MRI patterns to identify patients most likely to benefit.

Zhengzhou, Henan
NCT07047326Recruiting
Urokinase for acute ischemic stroke within 6 hours

This trial tests whether the clot-busting drug urokinase can help people who have had an ischemic stroke (a stroke caused by a blood clot). The goal is to dissolve the clot and improve recovery, as long as treatment starts within 6 hours of the first symptoms.

Beijing, Beijing Municipality
NCT07389460Not yet recruiting· Phase 3
Study of a clot-busting drug before thrombectomy for stroke

This trial tests giving a clot-dissolving medicine (rhPro-UK) through a vein before a procedure to remove a large blood clot in the brain. It is for people who had a stroke 4.5 to 24 hours ago and are already scheduled for clot removal. The goal is to see if the medicine helps improve blood flow and outcomes.

Lanzhou, Gansu
NCT06841978Not yet recruiting· Phase 3
Clot-dissolving treatment for recent stroke patients

This trial tests if a clot-dissolving medicine can help people who had a mild ischemic stroke and also had a prior stroke in the last 3 months. It aims to see if the treatment is safe and effective for this specific group.

Hear when a new Acute Ischemic Stroke trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.